Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma names Cynthia Butitta as CFO

She helped broker Pfizer’s takeover of NextWave Pharmaceuticals

Kite Pharma has named industry veteran Cynthia Butitta as chief financial officer.

Butitta was most recently chief financial officer of NextWave Pharmaceuticals and played a key role in the company's acquisition by Pfizer in October 2012.

Her other previous roles include chief financial officer and chief operating officer of Telik where she was responsible for securing over $450m through an initial public offering (IPO). She was also VP of finance at the biotech Connetics.

Kite Pharma is a biotech specialist in the burgeoning area of cancer immunotherapy products.

It has made a number of recent senior appointments in recent months – including several immunotherapy experts to its scientific advisory board and a chief medical officer – and Butitta is the latest hire to bolster its senior team.

“As a leading company in the emerging and highly promising field of immunotherapy, Kite has the opportunity to play a pivotal role in changing the way we approach cancer,” said Butitta.

10th January 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics